<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1" />
  <title>Oral Candidiasis – One‑Page Algorithm (NICE CKS 2025)</title>
  <style>
    :root {
      --bg: #0b1020;
      --surface: #12172a;
      --card: #171d34;
      --muted: #9fb0d1;
      --text: #eaf2ff;
      --accent: #7aa2ff;
      --accent-2: #27e1b9;
      --danger: #ff7a7a;
      --warn: #ffd166;
      --ok: #7dffba;
      --shadow: 0 10px 30px rgba(0,0,0,.35);
    }
    @media (prefers-color-scheme: light) {
      :root {
        --bg: #f6f8fc;
        --surface: #ffffff;
        --card: #ffffff;
        --muted: #5a6b8a;
        --text: #0f172a;
        --accent: #335dff;
        --accent-2: #0ea5a3;
        --danger: #e11d48;
        --warn: #b45309;
        --ok: #059669;
        --shadow: 0 8px 24px rgba(16,24,40,.08);
      }
    }

    * { box-sizing: border-box; }
    html, body { height: 100%; }

    body {
      margin: 0;
      font-family: ui-sans-serif, system-ui, -apple-system, Segoe UI, Roboto, "Helvetica Neue", Arial, "Noto Sans", "Apple Color Emoji", "Segoe UI Emoji";
      color: var(--text);
      background: radial-gradient(1200px 600px at 20% -10%, rgba(122,162,255,.15), transparent 60%),
                  radial-gradient(1000px 500px at 120% 20%, rgba(39,225,185,.12), transparent 60%),
                  var(--bg);
      line-height: 1.55;
    }

    .container {
      max-width: 1100px;
      margin: 0 auto;
      padding: 24px clamp(16px, 2.5vw, 32px) 80px;
    }

    header.hero {
      position: sticky;
      top: 0;
      z-index: 10;
      backdrop-filter: blur(8px);
      background: linear-gradient(180deg, rgba(17,24,39,.7), rgba(17,24,39,.25) 80%, transparent);
      border-bottom: 1px solid rgba(255,255,255,.08);
    }

    .title {
      display: flex;
      align-items: center;
      gap: 14px;
      padding: 12px 0 16px;
    }

    .logo {
      width: 40px; height: 40px; flex: none;
      display: grid; place-items: center;
      border-radius: 12px;
      background: linear-gradient(135deg, var(--accent), var(--accent-2));
      box-shadow: var(--shadow);
      color: white;
      font-weight: 800;
      letter-spacing: .5px;
    }

    h1 {
      margin: 0;
      font-size: clamp(22px, 2.4vw, 32px);
      letter-spacing: .2px;
    }
    .subtitle { margin: 2px 0 0; color: var(--muted); font-size: 14px; }

    .toolbar {
      display: flex; flex-wrap: wrap; gap: 8px; margin: 10px 0 18px;
    }
    .btn {
      appearance: none; border: 1px solid rgba(255,255,255,.14); color: var(--text);
      background: linear-gradient(180deg, rgba(255,255,255,.06), rgba(255,255,255,.03));
      padding: 10px 12px; border-radius: 12px; cursor: pointer; font-weight: 600; font-size: 14px;
      display: inline-flex; align-items: center; gap: 8px; box-shadow: var(--shadow);
    }
    .btn svg { width: 18px; height: 18px; }

    /* Layout */
    .grid {
      display: grid;
      grid-template-columns: repeat(12, 1fr);
      gap: 16px;
    }
    .card {
      grid-column: span 12;
      background: linear-gradient(180deg, rgba(255,255,255,.06), rgba(255,255,255,.03));
      border: 1px solid rgba(255,255,255,.12);
      border-radius: 16px; padding: 18px 18px 14px; box-shadow: var(--shadow);
    }
    .card h2 { margin: 0 0 8px; font-size: 18px; letter-spacing: .2px; }
    .card .kicker { color: var(--muted); font-size: 12px; text-transform: uppercase; letter-spacing: .18em; }
    .card ul { margin: 8px 0 6px 18px; }
    .card li { margin: 6px 0; }

    @media (min-width: 900px) {
      .col-4 { grid-column: span 4; }
      .col-6 { grid-column: span 6; }
      .col-8 { grid-column: span 8; }
    }

    /* Pills */
    .pill {
      display: inline-flex; align-items: center; gap: 8px;
      padding: 6px 10px; border-radius: 999px; font-size: 12px; font-weight: 700;
      background: rgba(255,255,255,.06); border: 1px solid rgba(255,255,255,.14);
    }
    .pill .dot { width: 8px; height: 8px; border-radius: 999px; }

    /* Tabs (CSS‑only) */
    .tabs { margin-top: 4px; }
    .tabs input { display: none; }
    .tab-nav { display: flex; flex-wrap: wrap; gap: 8px; margin: 6px 0 10px; }
    .tab-nav label {
      cursor: pointer; padding: 10px 12px; border-radius: 12px; font-weight: 700; font-size: 14px;
      background: rgba(255,255,255,.06); border: 1px solid rgba(255,255,255,.14);
    }
    .tabs .panel { display: none; border-top: 1px dashed rgba(255,255,255,.18); padding-top: 10px; }
    #t1:checked ~ .tab-wrap #p1,
    #t2:checked ~ .tab-wrap #p2,
    #t3:checked ~ .tab-wrap #p3,
    #t4:checked ~ .tab-wrap #p4 { display: block; }
    #t1:checked ~ .tab-nav label[for="t1"],
    #t2:checked ~ .tab-nav label[for="t2"],
    #t3:checked ~ .tab-nav label[for="t3"],
    #t4:checked ~ .tab-nav label[for="t4"] { outline: 2px solid var(--accent); }

    /* Callouts */
    .callout { border-left: 4px solid var(--accent); padding: 10px 12px; background: rgba(122,162,255,.08); border-radius: 10px; }
    .callout.warn { border-left-color: var(--warn); background: rgba(255,209,102,.12); }
    .callout.danger { border-left-color: var(--danger); background: rgba(255,122,122,.10); }

    /* Footer note */
    footer { color: var(--muted); font-size: 12px; margin-top: 18px; text-align: center; }

    /* Print (A4 one‑pager) */
    @page { size: A4; margin: 10mm; }
    @media print {
      body { background: #fff; }
      header.hero { position: static; background: none; border: none; }
      .toolbar { display: none; }
      .container { padding: 0; }
      .card { break-inside: avoid; box-shadow: none; border-color: #e5e7eb; background: #fff; }
      .tab-nav label { border-color: #e5e7eb; }
    }
  </style>
</head>
<body>
  <header class="hero">
    <div class="container">
      <div class="title">
        <div class="logo" aria-hidden="true">OC</div>
        <div>
          <h1>Oral Candidiasis – One‑Page Algorithm</h1>
          <p class="subtitle">NICE CKS 2025 • Clinician quick reference for rapid decision‑making (primary care)</p>
        </div>
      </div>
      <div class="toolbar">
        <button class="btn" onclick="window.print()" title="Print this one‑pager">
          <svg viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="1.6" stroke-linecap="round" stroke-linejoin="round" aria-hidden="true">
            <path d="M6 9V2h12v7"/><path d="M6 13H5a3 3 0 0 1-3-3 3 3 0 0 1 3-3h14a3 3 0 1 1 0 6h-1"/><path d="M6 22h12v-6H6z"/>
          </svg>
          Print
        </button>
        <span class="pill" title="Designed to fit on one printed page">
          <span class="dot" style="background: var(--ok)"></span>One‑pager
        </span>
        <span class="pill" title="Evidence‑based summary">
          <span class="dot" style="background: var(--accent)"></span>NICE CKS 2025
        </span>
      </div>
    </div>
  </header>

  <main class="container">
    <section class="grid">
      <article class="card col-4">
        <div class="kicker">Step 1</div>
        <h2>Confirm diagnosis</h2>
        <ul>
          <li><strong>Thrush (pseudomembranous):</strong> white/yellow plaques that wipe off → erythematous base.</li>
          <li><strong>Erythematous:</strong> sore, red tongue/palate; smooth dorsal tongue.</li>
          <li><strong>Denture stomatitis:</strong> redness under dentures; usually not sore.</li>
          <li><strong>Angular cheilitis:</strong> sore fissures at mouth corners (Candida ± <em>S. aureus</em>).</li>
          <li><strong>Chronic plaque‑like:</strong> adherent white plaques; malignancy risk.</li>
          <li><strong>Median rhomboid glossitis:</strong> central red depapillated area.</li>
        </ul>
        <div class="callout">
          <strong>Think differentials:</strong> leukoplakia, lichen planus, geographic tongue, hairy tongue, oral cancer, HIV.
        </div>
      </article>

      <article class="card col-4">
        <div class="kicker">Step 2</div>
        <h2>Red flags → admit / urgent refer</h2>
        <ul>
          <li><strong>Systemic illness/candidaemia.</strong></li>
          <li><strong>Oesophageal involvement:</strong> dysphagia, odynophagia, retrosternal pain.</li>
          <li>Severe, extensive, recurrent, atypical, or non‑responsive disease.</li>
          <li>Suspicion of malignancy (chronic plaque‑like).</li>
        </ul>
        <div class="callout danger"><strong>Lower threshold</strong> for admission when markedly immunocompromised.</div>
      </article>

      <article class="card col-4">
        <div class="kicker">Step 3</div>
        <h2>Identify risk factors</h2>
        <ul>
          <li>Extremes of age; xerostomia.</li>
          <li>Diabetes, HIV/AIDS; chemo/radiotherapy; systemic or inhaled steroids; DMARDs.</li>
          <li>Recent broad‑spectrum antibiotics.</li>
          <li>Dentures; poor oral hygiene; local trauma; smoking.</li>
          <li>Nutritional/haematinic deficiency.</li>
        </ul>
      </article>
    </section>

    <section class="grid">
      <article class="card col-8">
        <div class="kicker">Step 4</div>
        <h2>Management by group</h2>
        <div class="tabs">
          <input type="radio" name="tabs" id="t1" checked>
          <input type="radio" name="tabs" id="t2">
          <input type="radio" name="tabs" id="t3">
          <input type="radio" name="tabs" id="t4">

          <div class="tab-nav">
            <label for="t1">Children (not immunocompromised)</label>
            <label for="t2">Adults (not immunocompromised)</label>
            <label for="t3">Adults on immunosuppressive Tx</label>
            <label for="t4">Adults with HIV</label>
          </div>

          <div class="tab-wrap">
            <div class="panel" id="p1">
              <ul>
                <li><strong>Admit</strong> if systemic / oesophageal disease; <strong>refer</strong> if severe/extensive.</li>
                <li><strong>Topical first‑line:</strong> <em>Miconazole oral gel</em> (≥4 months; unlicensed &lt;4 m / preterm &lt;5–6 m). Continue ≥7 days after resolution.</li>
                <li><strong>Alternative:</strong> <em>Nystatin suspension</em> (unlicensed in neonates).</li>
                <li><strong>Review/Refer:</strong> no adequate response after 2 weeks; recurrent episodes; consider underlying immunodeficiency / risk factors.</li>
              </ul>
            </div>

            <div class="panel" id="p2">
              <ul>
                <li><strong>Mild/local:</strong> topical therapy.
                  <ul>
                    <li><strong>1st line:</strong> <em>Miconazole oral gel</em>.</li>
                    <li><strong>Alt:</strong> <em>Nystatin suspension</em> (7 days, then 48 h after lesions resolve).</li>
                  </ul>
                </li>
                <li><strong>Extensive/severe:</strong> <em>Fluconazole PO</em> 200–400 mg day 1, then 100–200 mg OD for 7–21 d.</li>
                <li><strong>Advice:</strong> oral hygiene; smoking cessation; spacer/rinse with inhaled steroids; denture care (see below); review diabetes control.</li>
                <li><strong>Follow‑up:</strong> review at ~14 d; extend/adjust or refer if unresolved. Low threshold for early referral if severe.</li>
              </ul>
            </div>

            <div class="panel" id="p3">
              <ul>
                <li><strong>Lower threshold</strong> to admit if systemic / oesophageal symptoms.</li>
                <li><strong>Seek specialist advice</strong> before Tx if on <em>ciclosporin</em>, <em>tacrolimus</em>, or receiving <em>chemotherapy</em>.</li>
                <li><strong>Mild/local:</strong> topical therapy — <em>miconazole</em> (1st) or <em>nystatin</em>.</li>
                <li><strong>Extensive/severe:</strong> <em>Fluconazole PO</em> 200–400 mg day 1, then 100–200 mg OD for 7–21+ d as needed.</li>
                <li><strong>Review:</strong> at 7–14 d; extend/switch or refer if not fully effective; swab if persistent; ensure DMARD monitoring.</li>
              </ul>
            </div>

            <div class="panel" id="p4">
              <ul>
                <li><strong>Admit</strong> if systemic/oesophageal; lower threshold if markedly immunocompromised.</li>
                <li><strong>First‑line:</strong> <em>Fluconazole PO</em> 200–400 mg day 1, then 100–200 mg OD for 7–14 d (if otherwise well and not on prophylaxis).</li>
                <li><strong>Seek specialist advice</strong> if severe/extensive or prior fluconazole failure.</li>
                <li><strong>Review:</strong> at ~7 d; extend another 7 d or refer/swap if unresolved; swab if persistent.</li>
              </ul>
            </div>
          </div>
        </div>
      </article>

      <article class="card col-4">
        <div class="kicker">Quick safety</div>
        <h2>Key prescribing notes</h2>
        <ul>
          <li><strong>Miconazole oral gel</strong> — avoid with: <u>warfarin</u> (contraindicated; ↑INR, bleeding risk), <u>QT‑prolonging agents</u>, <u>simvastatin</u>, <u>quetiapine</u>, <u>triazolam/oral midazolam</u>, <u>ergotamine</u>. Caution with sulfonylureas (↑hypoglycaemia), phenytoin, Ca‑channel blockers, ciclosporin, tacrolimus, sirolimus.</li>
          <li><strong>Nystatin suspension</strong> — fewer interactions; suitable alternative when miconazole contraindicated.</li>
          <li><strong>Fluconazole</strong> — adjust for renal impairment; interactions incl. warfarin and sulfonylureas; <em>avoid in pregnancy</em>. Manufacturers advise ~1‑week washout pre‑conception.</li>
        </ul>
        <div class="callout warn"><strong>Infants:</strong> Do not apply miconazole to the back of the throat; divide doses; observe for choking. Avoid miconazole in &lt;4 months (unlicensed), or &lt;5–6 months if pre‑term.</div>
      </article>
    </section>

    <section class="grid">
      <article class="card col-6">
        <div class="kicker">Step 5</div>
        <h2>Supportive & preventive measures</h2>
        <ul>
          <li><strong>Dentures:</strong> remove ≥6 h/day (longer if inflamed); brush then disinfect (e.g., chlorhexidine/hexetidine or baby‑bottle sterilizing solutions if no metal); air‑dry; brush mucosa; correct fit.</li>
          <li><strong>Inhaled steroids:</strong> check technique; rinse/brush after use; spacer; step down dose when appropriate.</li>
          <li><strong>Diabetes:</strong> review and optimize control (especially if recurrent).</li>
          <li><strong>Smoking:</strong> offer cessation support.</li>
          <li><strong>Oral hygiene:</strong> routine dental care; address xerostomia and local trauma.</li>
        </ul>
      </article>

      <article class="card col-6">
        <div class="kicker">Pocket checklist</div>
        <h2>Follow‑up & referral</h2>
        <ul>
          <li><strong>Children:</strong> refer if severe/extensive or no response by 2 weeks.</li>
          <li><strong>Adults (non‑immunocompromised):</strong> review at ~14 d; extend fluconazole 7 d if partial; refer/specialist input if persistent.</li>
          <li><strong>Immunosuppressive Tx:</strong> review 7–14 d; early specialist advice for calcineurin inhibitors/chemo.</li>
          <li><strong>HIV:</strong> review ~7 d; extend 7 d if needed; refer if recurrent/breakthrough on prophylaxis.</li>
          <li><strong>Biopsy:</strong> chronic plaque‑like disease unresponsive to Tx (malignancy risk).</li>
        </ul>
      </article>
    </section>

    <footer>
      Prepared as a rapid reference from your practice guidance. Always check local formulary/BNF for dosing, contraindications, and interactions.
    </footer>
  </main>
</body>
</html>
